NFKB2 and renal carcinoma: Similarly, patients with low neoantigen load and low NFKB2 mRNA expression in their renal carcinoma cell type had a better survival prognosis than those with high NFKB2 expression and a significantly higher survival time than the patients with a low mutational rate (Figure 14).